This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wallet, F.
Right arrow Articles by Courcol, R. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wallet, F.
Right arrow Articles by Courcol, R. J.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, June 2002, p. 2300-2301, Vol. 40, No. 6
0095-1137/02/$04.00+0     DOI: 10.1128/JCM.40.6.2300-2301.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Pneumonia Due to Bordetella bronchiseptica in a Cystic Fibrosis Patient: 16S rRNA Sequencing for Diagnosis Confirmation

Frédéric Wallet,1* Thierry Perez,2 Sylvie Armand,1 Benoit Wallaert,2 and René J. Courcol1

Laboratoire de Bactériologie-Hygiène,1 Département de Pneumologie, Hôpital A. Calmette, CHRU de Lille, Lille, France2

Received 3 December 2001/ Returned for modification 21 January 2002/ Accepted 12 February 2002


arrow
ABSTRACT
 
Bordetella bronchiseptica was identified as an unusual etiologic agent of pulmonary recurrent exacerbations and pneumonia in a cystic fibrosis (CF) patient by utilizing a 16S rRNA molecular kit in our hospital's clinical laboratory. This method appears to be a useful approach for identifying new emerging CF pathogens when discrepancies exist between phenotypical tests.


arrow
CASE REPORT
 
A 27-year-old female patient was diagnosed with cystic fibrosis (CF) at the age of 4 years after persistent pulmonary disease. The diagnosis was confirmed by sweat test and genotype assay showing a homozygous {Delta}F508 mutation of the CF transmembrane conductor regulation gene. Bronchial colonization with Staphylococcus aureus had been noticed since childhood and diffuse bronchiectasis had been confirmed by computed tomography scan. She was never colonized by Pseudomonas aeruginosa. In April 1999, the patient was admitted to the respiratory care unit for a pulmonary exacerbation with a fever of 38°C, dyspnea, increased sputum, and a significant spirometric deterioration (forced expiratory volume in 1 s [FEV1] = 1.2 liters, versus 1.4 liters in October 1998; 15% decrease from baseline). In the mucopurulent sputum both S. aureus (108 CFU/ml) and an unusual gram-negative bacillus (108 CFU/ml) were isolated and quantified (1). After the failure of oxacillin treatment, an intravenous antimicrobial treatment (ticarcillin, 250 mg/kg of body weight/day, plus tobramycin, 10 mg/kg/day) was administered for 15 days and the patient clinically recovered. During the follow-up between May 1999 to October 2001, she presented with two episodes of pneumonia in the left lower lobe and two exacerbations. On each occasion, a gram-negative bacillus and S. aureus were isolated in the sputum. In October 2001, her FEV1 under stable condition had significantly decreased to 0.95 liter. This patient lived in town and did not have any pets at home.

In each exacerbation and in the two episodes of pneumonia, sputum was cultured for aerobic organisms. Cultures on bromocresol purple, blood agar, and chocolate agar plates yielded a bacillus culture mixed with S. aureus. Gram staining from the bacillus culture showed small gram-negative coccobacilli. This rod was catalase and oxidase positive, motile, non-spore-forming, and strictly aerobic. It was able to reduce nitrate to nitrite, and it did not produce indole. Phenotypical identification performed with the API 20NE system (bioMérieux, Marcy l'Etoile, France) with an inoculum of 0.5 McFarland standard confirmed Bordetella bronchiseptica (code no. 1200066; p = 99%; T = 0.84), whereas the identification performed with the API 32GN system gave Pseudomonas alcaligenes (code no. 00170063022; p = 95%; T = 0.95). The discrepancy between these two phenotypical identifications and the fact that the rod did not rapidly hydrolyze urease prompted us to use the Microseq 500 16S ribosomal DNA bacterial sequencing kit (Applied Biosystems, Foster City, Calif.). A 496-bp portion of the amplified DNA was sequenced with an automated DNA sequencer (ABI Prism 377; Applied Biosystems). These 496 bp were compared with National Center for Biotechnology Information GenBank entries by using the BLAST algorithm, giving 100% homology with B. bronchiseptica (accession no. X 57026) and B. pertussis (accession no. AF 142327). P. alcaligenes was not indicated in the BLAST algorithm results. The molecular identification of B. bronchiseptica was the most reliable one, corresponding to the API 20NE phenotypical identification, since the bacteria grow on simple nutritive medium (bromocresol purple). B. pertussis needs enriched media such as Bordet-Gengou or Regan-Lowe medium to grow and does not grow on simple medium. At last, the in vitro susceptibility tests using a disk diffusion technique on Mueller-Hinton agar according to the Antibiogram Committee of the French Microbiology Society (15) showed that this bacterium was susceptible to ticarcillin, piperacillin, ceftazidime, imipenem, gentamicin, tobramycin, trimethoprim-sulfamethoxazole, and doxycycline and resistant to fluoroquinolones.

B. bronchiseptica is generally a common commensal or pathogen in the respiratory tract of several mammalian species (18). Since 1975, fewer than 50 cases of respiratory infections have been published. They were mainly found in immunocompromised patients and were often associated with animals (2, 6, 8, 11, 13). Among the new emerging pathogens in CF (e.g., Stenotrophomonas maltophilia, Burkholderia cepacia, and Alcaligenes xylosoxidans), B. bronchiseptica has not been mentioned in recent reviews (3, 4). This is why our first identification of B. bronchiseptica by the API ID20 NE system had to be confirmed by another phenotypical method. The API ID 32GN system giving P. alcaligenes was perhaps most plausible in the context of CF. Moreover, the case described by Peltroche-Llacsahuanga et al. (12), reporting a misidentification of A. xylosoxidans as B. bronchiseptica by an API ID20 NE system, was a good reason to check our identification with another method (7). The genotypical approach utilizing a 16S rRNA molecular sequencing method allowed us to confirm rapidly and with good agreement the identification of B. bronchiseptica. When an unusual microorganism is identified in CF patients, the main question is whether it plays a role in pulmonary deterioration. Such uncertainties remain for pathogens such as S. maltophilia (3). A follow-up over 2 years for our patient showed a significant deterioration of pulmonary function. Such a decline appears unusual for patients with long-term isolated S. aureus colonization. In addition, oxacillin treatment during initial exacerbations did not provide a clinical response. The role of B. bronchiseptica in lung disease remains unclear, but the ability of this bacterium to inhibit leukocyte function and to adhere to respiratory epithelial cells explains the seriousness of the infection and the persistence in the lower respiratory tract (8, 9, 16). Moreover, immunocompetent patients have been described as infected by B. bronchiseptica (14, 16, 17). In our patient, the two pneumonias developed while she was pregnant. Finally, a strict questioning of the patient revealed that several months prior to the first exacerbation of bronchitis, which occurred 3 years ago, she practiced occasional horse riding, which could explain the colonization of the respiratory tract of the patient by B. bronchiseptica (5, 10). B. bronchiseptica could potentiate the obstructive lung disease by altering the ciliary kinesia and thus reducing mucociliary clearance and local defenses.


arrow
FOOTNOTES
 
* Corresponding author. Mailing address: Laboratoire de Bactériologie-Hygiène, Blvd. du Pr Leclercq, 59037 Lille Cedex, France. Phone: 03 20 44 54 80. Fax: 03 20 44 48 95. E-mail: fwallet{at}chru-lille.fr. Back


arrow
REFERENCES
 
    1
  1. Bartlett, J. G., K. J. Ryan, T. F. Smith, and W. R. Wilson. 1987. Cumitech 7A, Laboratory diagnosis of lower respiratory tract infections. Coordinating ed., J. A. Washington II. American Society for Microbiology, Washington, D.C.
    2. 2
  2. Bauwens, J. E., D. H. Spach, T. W. Schacker, M. M. Mustafa, and R. A. Bowden. 1992. Bordetella bronchiseptica pneumonia and bacteremia following bone marrow transplantation. J. Clin. Microbiol. 30:2474-2475.[Abstract/Free Full Text]
    3. 3
  3. Beringer, P. M., and M. D. Appleman. 2000. Unusual respiratory bacterial flora in cystic fibrosis: microbiologic and clinical features. Curr. Opin. Pulm. Med. 6:545-550.[CrossRef][Medline]
    4. 4
  4. Burns, J. L., J. Emerson, J. R. Stapp, D. L. Yim, J. Krzewinski, L. Louden, B. W. Ramsey, and C. R. Clausen. 1998. Microbiology of sputum from patients at cystic fibrosis centers in the United States. Clin. Infect. Dis. 27:158-163.[Medline]
    5. 5
  5. Chrisley, R. M., D. R. Hodgson, R. J. Rose, J. L. Wood, S. W. Reids, K. G. Whitear, and J. L. Hodgson. 2001. A case-control study of respiratory disease in thoroughbred racehorses in Sydney, Australia. Equine Vet. J. 33:221-223.[Medline]
    6. 6
  6. Garcia san Miguel, L., C. Quereda, M. Martinez, P. Martin-Davila, J. Cobo, and A. Guerrero. 1998. Bordetella bronchiseptica cavitary pneumonia in a patient with AIDS. Eur. J. Clin. Microbiol. Infect. Dis. 17:675-676.[Medline]
    7. 7
  7. Gerlach, G., F. von Wintzingerode, B. Middendorf, and R. Gross. 2001. Evolutionary trends in the genus Bordetella. Microb. Infect. 3:61-72.[CrossRef][Medline]
    8. 8
  8. Gueirard, P., C. Weber, A. Le Coustumier, and N. Guiso. 1995. Human Bordetella bronchiseptica infection related to contact with infected animals: persistence of bacteria in host. J. Clin. Microbiol. 33:2002-2006.[Abstract]
    9. 9
  9. Harvill, E. T., A. Preston, P. A. Cotter, A. G. Allen, D. J. Maskell, and J. F. Miller. 2000. Multiple roles for Bordetella lipopolysaccharide molecules during respiratory tract infection. Infect. Immun. 68:6720-6728.[Abstract/Free Full Text]
    10. 10
  10. Hoffman, A. M., L. Viel, J. F. Prescott, S. Rosendal, and J. Thorsen. 1993. Association of microbiologic flora with clinical, endoscopic, and pulmonary cytologic findings in foals with distal respiratory tract infection. Am. J. Vet. Res. 54:1515-1522.
    11. 11
  11. Papasian, C. J., N. J. Downs, R. L. Talley, D. J. Romberger, and G. R. Hodges. 1987. Bordetella bronchiseptica bronchitis. J. Clin. Microbiol. 25:575-577.[Abstract/Free Full Text]
    12. 12
  12. Peltroche-Llacsahuanga, H., G. Haase, and H. Kentrup. 1998. Persistent airway colonization with Alcaligenes xylosoxidans in two brothers with cystic fibrosis. Eur. J. Clin. Microbiol. Infect. Dis. 17:132-134.[Medline]
    13. 13
  13. Petrocheilou, V., K. Georgilis, E. Kostis, H. Prifti, N. Zakopoulos, and S. Stamalopoulos. 2000. Bronchitis caused by Bordetella bronchiseptica in an elderly woman. Clin. Microbiol. Infect. 6:147-148.[CrossRef][Medline]
    14. 14
  14. Re, V. L., III, P. J. Brenan, J. Wadlin, R. Weaver, and I. Nachamkin. 2001. Infected branchial cleft cyst due to Bordetella bronchiseptica in an immunocompetent patient. J. Clin. Microbiol. 39:4210-4212.[Abstract/Free Full Text]
    15. 15
  15. Soussy, C. J., G. Carret, J. D. Cavallo, H. Chardon, C. Chidiac, P. Choutet, P. Courvalin, H. Dabernat, H. Drugeon, L. Dubreuil, F. Goldstein, V. Jarlier, R. Leclercq, M. H. Nicolas-Chanoine, A. Philippon, C. Quentin, B. Rouveix, and J. Sirot. 2000. Report of the Antibiogram Committee of the French Microbiology Society, 2000-2001. Pathol. Biol. 48:832-871.[Medline]
    16. 16
  16. Stefanelli, P., P. Mastrantonio, S. Z. Hausman, M. Giuliano, and D. L. Burns. 1997. Molecular characterization of two Bordetella bronchiseptica strains isolated from children with coughs. J. Clin. Microbiol. 35:1550-1555.[Abstract]
    17. 17
  17. Tamion, F., C. Giraud, V. Chevron, M. Pestel, and G. Bonmarchand. 1996. Bordetella bronchiseptica pneumonia with shock in an immunocompetent patient. Scand. J. Infect. Dis. 28:197-198.[Medline]
    18. 18
  18. Woolfrey, B. F., and J. A. Moody. 1991. Human infections associated with Bordetella bronchiseptica. Clin. Microbiol. Rev. 4:243-255.[Abstract/Free Full Text]

Journal of Clinical Microbiology, June 2002, p. 2300-2301, Vol. 40, No. 6
0095-1137/02/$04.00+0     DOI: 10.1128/JCM.40.6.2300-2301.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Schmoldt, S., Latzin, P., Heesemann, J., Griese, M., Imhof, A., Hogardt, M. (2006). Clonal analysis of Inquilinus limosus isolates from six cystic fibrosis patients and specific serum antibody response.. J Med Microbiol 55: 1425-1433 [Abstract] [Full Text]  
  • Wellinghausen, N., Kothe, J., Wirths, B., Sigge, A., Poppert, S. (2005). Superiority of Molecular Techniques for Identification of Gram-Negative, Oxidase-Positive Rods, Including Morphologically Nontypical Pseudomonas aeruginosa, from Patients with Cystic Fibrosis. J. Clin. Microbiol. 43: 4070-4075 [Abstract] [Full Text]  
  • Mattoo, S., Cherry, J. D. (2005). Molecular Pathogenesis, Epidemiology, and Clinical Manifestations of Respiratory Infections Due to Bordetella pertussis and Other Bordetella Subspecies. Clin. Microbiol. Rev. 18: 326-382 [Abstract] [Full Text]  
  • Muyldermans, G., Soetens, O., Antoine, M., Bruisten, S., Vincart, B., Doucet-Populaire, F., Fry, N. K., Olcen, P., Scheftel, J. M., Senterre, J. M., van der Zee, A., Riffelmann, M., Pierard, D., Lauwers, S. (2005). External Quality Assessment for Molecular Detection of Bordetella pertussis in European Laboratories. J. Clin. Microbiol. 43: 30-35 [Abstract] [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wallet, F.
Right arrow Articles by Courcol, R. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wallet, F.
Right arrow Articles by Courcol, R. J.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»